

CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8⁺ T Cells—Letter

Martin Thelen¹, Axel Lechner^{1,2}, Kerstin Wennhold¹,
Michael von Bergwelt-Baildon^{1,3,4,5,6}, and Hans A. Schlößer^{1,7}



With great interest we read the article "CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8⁺ T Cells" published by Canale and colleagues in *Cancer Research* (1). Previously, expression of CD39 has been described mainly for regulatory T cells (2) and the relevance of CD39 as a mecha-

nism of immune escape in cancer was further highlighted by observation that CD39 is expressed on cancer cells (3). Because exhausted T cells, the target population of immune checkpoint inhibition, do not express high levels of CD39 (4), it might be a promising strategy to create a synergistic effect




Figure 1.

CD39⁺CD8⁺ T cells are increased in tumor samples. PBMCs were isolated using density centrifugation. Tissue samples were mechanically and enzymatically digested using a gentleMACS dissociator with 320 U/mL Collagenase IV and 100 U/mL DNase I for 1 hour at 37°C on a shaking incubator. Cells were freshly stained and analyzed (Gallios cytometer and Kaluza analysis software). Samples were gated for living cells (viability dye) and T cells (CD3⁺CD45⁺). **A**, Exemplary density plots of CD39⁺CD8⁺ T cells in PBMCs, healthy renal tissue, and tumor of one patient with renal cell carcinoma (RCC). **B**, Scatter plots showing results of flow cytometric analysis of CD8⁺CD39⁺ T cells in PBMC and single-cell suspensions of healthy tissue and tumor samples. HC, healthy controls. Means of lymphocytic subsets were compared using one-way ANOVA with Sidak multiple comparison test (Graphpad Prism 7). Data are presented as individuals with mean ± SD. ns, nonsignificant; *, $P \leq 0.05$; ****, $P \leq 0.0001$.

¹Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany. ²Department of Head and Neck Surgery, University of Cologne, Cologne, Germany. ³Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany. ⁴Department I of Internal Medicine I, University of Cologne, Cologne, Germany. ⁵German Cancer Consortium (DKTK), Heidelberg, Germany. ⁶Comprehensive Cancer Center Munich (CCCM), Munich, Germany. ⁷Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany.

Corresponding Author: Martin Thelen, Center for Molecular Medicine Cologne, University of Cologne, Robert-Koch Straße 21, 50931 Cologne, Germany. E-mail: martin.thelen@uk-koeln.de.

doi: 10.1158/0008-5472.CAN-18-0873

©2018 American Association for Cancer Research.

between immune checkpoint inhibition and CD39 targeting, thereby improving efficacy of immune checkpoint inhibition in cancer.

The authors observed that a subset of CD8⁺ T cells expresses the ATP-ecto-nucleotidase CD39 at similar levels as regulatory T cells. This CD8⁺CD39⁺ T-cell subset is enriched in tumor samples and almost absent in peripheral blood mononuclear cell (PBMC) or nonmetastatic tumor draining lymph nodes. Interestingly, enrichment of CD8⁺CD39⁺ T cells seems to be a common feature of preclinical tumor models (B16F10 and B16F10-OVA melanoma and MCA-OVA fibrosarcoma) as well as human melanoma and breast cancer. CD8⁺CD39⁺ T cells increased with tumor progression in the B16F10-OVA melanoma model. These cells were present in parental B16F10 melanoma, but the fraction was generally higher in highly immunogenic tumors expressing ovalbumin.

Although the presented study provides first evidence for a relevance of this cellular subset in human cancer, the data are limited to breast cancer and lymph node metastases of melanoma. We analyzed relevance of this highly interesting T-cell subset in four additional tumor entities. We could confirm presence of CD8⁺CD39⁺ T cells in head and neck squamous cell carcinoma, renal cell carcinoma, non-small cell lung cancer, and gastric

adenocarcinoma (Fig. 1). In our opinion, the present study lacks a comparison with normal healthy tissue, which we provide in this letter. In accordance with data from PBMCs, CD8⁺CD39⁺ T cells were significantly decreased in healthy normal mucosa compared with three of the four tumor entities. Our own data further support relevance of this T-cell subset in four additional types of cancer and we demonstrate that this subset is highly specific for the tumor microenvironment regardless of the tumor origin. Taken together, the presented study and our data provide further translation evidence for clinical application of CD39 inhibition in basket trials.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

This work was supported by a German Research Foundation grant (325827080 to H.A. Schlößer) and a Wilhelm Sander research grant (to H.A. Schlößer).

Received March 23, 2018; revised April 23, 2018; accepted June 18, 2018; published first August 15, 2018.

References

1. Canale FP, Ramello MC, Núñez N, Furlan CLA, Bossio SN, Serrán MG, et al. CD39 expression defines cell exhaustion in tumor-infiltrating CD8⁺ T cells. *Cancer Res* 2018;78:115–28.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012;12:252–64.
3. Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. *Cancer Immunol Res* 2015;3:254–65.
4. Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, et al. Defining CD8⁺ T cells that provide the proliferative burst after PD-1 therapy. *Nature* 2016;537:417–21.